Merck & Co. Inc (6MK HM) stock market data APIs
€69.2599
1(1.4%)
as of September 15, 2025
Try our APIs with
free plan!
Merck & Co. Inc Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for 6MK.HM.
Prev. Close
69.2599
Open
70.2646
High
70.2646
Low
68.3304
52 wk Range
64.3385-103.3717
Market Cap
162 424 M
Dividends (Yield)
0.0234
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Merck & Co. Inc data using free add-ons & libraries
Get Merck & Co. Inc Fundamental Data
Merck & Co. Inc Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Merck & Co. Inc News
New
Merck (MRK) And Daiichi Sankyo's R-DXd Receives FDA Breakthrough Therapy Designation
Merck experienced a 6% rise in its share price over the last quarter, coinciding with significant developments such as the FDA granting Breakthrough Therapy Designation for raludotatug deruxtecan—a ...
Truist Initiates Coverage on Janux Therapeutics (JANX) with a Buy Rating, $100 PT
Janux Therapeutics Inc. (NASDAQ:JANX) is one of the best up and coming stocks with huge upside potential. On September 10, Truist initiated coverage of Janux Therapeutics with a Buy rating and $100 pr...
Raludotatug Deruxtecan Granted Breakthrough Therapy Designation by U.S. FDA for Patients with CDH6 Expressing Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancers Previously Treated with Bevacizumab
First Breakthrough Therapy Designation for Daiichi Sankyo and Merck’s raludotatug deruxtecan based on phase 1 trial and REJOICE-Ovarian01 phase 2/3 trial Second Breakthrough Therapy Designation sinc...
How Bad Is This Sector’s Health Scare?
Do not buy healthcare fund if you are allergic to any of its ingredients. After a rough stretch, some investors were prepared to ignore the warning label and bet on the beaten-down sector this year. F...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
